Timothy A. Springer - 13 Nov 2023 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
Director, 10%+ Owner
Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Timothy A. Springer
Issuer symbol
RNAC
Transactions as of
13 Nov 2023
Net transactions value
+$59,930,248
Form type
4
Filing time
15 Nov 2023, 17:20:10 UTC
Previous filing
30 Jun 2023
Next filing
04 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SELB Series A Convertible Preferred Stock Award $9,999,999 +24,785 $403.47* 24,785 15 Nov 2023 See Footnote F1
transaction SELB Series A Convertible Preferred Stock Award $49,999,998 +123,925 $403.47* 123,925 15 Nov 2023 Direct
holding SELB Common Stock 86,418 13 Nov 2023 By wife
holding SELB Common Stock 7,293,625 13 Nov 2023 Direct
holding SELB Common Stock 29,868,490 13 Nov 2023 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SELB Stock Option (Right to Buy) Disposed to Issuer -6,410 -100% 0 13 Nov 2023 Common Stock 6,410 $17.47 Direct F2
transaction SELB Stock Option (Right to Buy) Disposed to Issuer -10,000 -100% 0 13 Nov 2023 Common Stock 10,000 $12.75 Direct F3
transaction SELB Stock Option (Right to Buy) Disposed to Issuer -10,000 -100% 0 13 Nov 2023 Common Stock 10,000 $2.10 Direct F4
transaction SELB Stock Option (Right to Buy) Disposed to Issuer -20,000 -100% 0 13 Nov 2023 Common Stock 20,000 $3.00 Direct F5
transaction SELB Stock Option (Right to Buy) Disposed to Issuer -40,000 -100% 0 13 Nov 2023 Common Stock 40,000 $4.01 Direct F6
transaction SELB Stock Option (Right to Buy) Disposed to Issuer -40,000 -100% 0 13 Nov 2023 Common Stock 40,000 $3.31 Direct F7
transaction SELB Stock Option (Right to Buy) Disposed to Issuer $69,750 -75,000 -100% $0.9300 0 13 Nov 2023 Common Stock 75,000 $1.13 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.
F2 This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc.
F3 This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger.
F4 This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger.
F5 This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger.
F6 This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger.
F7 This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger.
F8 This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $69,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.